HOUSTON, Sept. 10, 2013 /PRNewswire/ -- The U.S. Department of Commerce's United States Patent and Trademark Office (USPTO) issued OrthoAccelTechnologies, Inc., a patent (No. 8,500,446, "Vibrating Orthodontic Remodeling Device") for its hands-free AcceleDent, an FDA-cleared, Class II medical device designed for faster orthodontic treatment with only 20 minutes of daily use. AcceleDent was introduced to the U.S. market in 2012 and is now offered at over 1,000 orthodontic locations nationwide.
A prescription-only medical device, AcceleDent is recommended by orthodontists who tout the device's SoftPulse Technology that enhances movements directed by orthodontics and accelerates tooth movement.
"Both the issuance of this patent and the rapid market adoption are important milestones for OrthoAccel. We believe they validate the distinct nature of our technology," said Kathleen Malaspina, OrthoAccel's chief innovation officer and vice president of marketing. "This patent award demonstrates OrthoAccel's commitment to innovation, and it further strengthens our overall portfolio of patents on AcceleDent's capabilities of moving teeth faster and enhancing orthodontic treatment."
AcceleDent's technology was developed in part by Dr. Jeremy Mao, professor of orthodontics and Zegarelli Endowed Chair at Columbia University College of Dental Medicine in New York. Mao's pioneering work in the early 2000s, which was initially conducted while he was a faculty member at the University of Illinois, Chicago, was paramount in establishing the therapeutic effect of pulsatile forces in accelerating bone modeling and remodeling in the orofacial region.
The product was first introduced to the global orthodontic market in 2009 and to the U.S. in 2012. The first U.S. patient to complete orthodontic treatment using AcceleDent was Frederick Churbuck, who completed a projected 18-month orthodontic treatment in just nine months.
"Our clinical studies and patient testimonials confirm AcceleDent's claims of being fast, safe and gentle, and this patent reinforces OrthoAccel's position as the industry's sole supplier of an FDA-cleared device that accelerates orthodontic treatment," said Michael K. Lowe, OrthoAccel's CEO. "The patent offers even more assurance to orthodontists who are recommending AcceleDent to their patients."
Lowe added that OrthoAccel has received positive feedback from key opinion leaders in the orthodontic industry who are seeing remarkable results firsthand within their own orthodontic practices. The timing for this product is also optimal, Lowe noted, because the industry is in a growth phase driven by adults who are seeking orthodontic treatment either for the first time or to complement treatment received in adolescence.
Orthodontists and staff members interested in learning more about AcceleDent Aura or how to offer the technology at their practice can locate an OrthoAccel sales representative at AcceleDent.com/orthodontists or call 866-866-4919.
About OrthoAccel® Technologies, Inc.
Based in Houston, Texas, OrthoAccel® Technologies, Inc. is a privately owned medical device company currently engaged in the development, manufacturing and marketing of products to enhance dental care and orthodontic treatment. OrthoAccel® developed and sells AcceleDent® Aura, the first FDA-cleared clinical approach to safely accelerate orthodontic tooth movement by applying gentle micropulses (SoftPulse Technology) as a complement to existing orthodontic treatment. More information can be found at www.acceledent.com and www.acceledent.co.uk or requested via email@example.com.
SOURCE OrthoAccel Technologies, Inc.